Tariquidar

Tariquidar

Tariquidar is a third-generation P-glycoprotein inhibitor, which is used in the field of pharmacology to enhance the effectiveness of certain drugs. It is a non-competitive inhibitor that has been shown to restore drug sensitivity in multidrug resistance.

History

Tariquidar was developed by Xenova Group, a British biotechnology company, in the late 1990s. The development of Tariquidar was part of a larger effort to combat multidrug resistance in cancer treatment.

Mechanism of Action

Tariquidar works by inhibiting the action of P-glycoprotein, a protein that pumps foreign substances out of cells. This protein is often overexpressed in cancer cells, leading to multidrug resistance. By inhibiting P-glycoprotein, Tariquidar allows more of the drug to remain in the cancer cells, increasing its effectiveness.

Clinical Trials

Several clinical trials have been conducted to test the effectiveness of Tariquidar. These trials have shown that Tariquidar can enhance the effectiveness of certain chemotherapy drugs in treating various types of cancer.

Side Effects

Like all drugs, Tariquidar has potential side effects. These can include nausea, vomiting, and diarrhea. More serious side effects can include heart problems and low blood cell counts.

Future Research

Future research on Tariquidar is focused on further understanding its mechanism of action and potential uses in cancer treatment. There is also interest in exploring its potential use in treating other diseases where multidrug resistance is a problem.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a oncology stub. You can help WikiMD by expanding it!